Have a history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational drug
Intolerance to or prior severe (?Grade ) allergic or anaphylactic reaction to infused antibodies or infused therapeutic proteins.
History of anaphylactic reaction to a recombinant protein or hypersensitivity to PEG
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
Patients with intolerance to or who have had a severe allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, or patients who have had a severe allergic or anaphylactic reaction to any of the substances included in the study drug (including excipients)
Patients with intolerance to or who have had a severe (>= grade ) allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, or patients who have had a severe allergic or anaphylactic reaction to any of the substances included in the investigational product (including excipients)
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
Severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of severe (defined as ? grade , using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version . [NCI-CTCAE] v current active minor version) allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients ( mM Tris buffered saline) in the investigational agent.
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
Hypersensitivity to the active substance or to any of the excipients for study drug BT, or history of severe allergic or anaphylactic reaction to therapeutic proteins (e.g. reaction to vaccination or to biological therapy)
History of severe (using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version . [NCI-CTCAE] v current minor version ? grade ) allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant protein
Hypersensitivity to recombinant proteins or excipients in elotuzumab, lenalidomide, or dexamethasone.
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in investigational product
Participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in TAK- formulation.
